Quest Diagnostics Inc (DGX) Upgraded at Zacks Investment Research


According to Zacks, "Quest Diagnostics delivered a better-than-expected third quarter with respect to earnings while closely missing the Zacks Consensus Estimate on the revenue front. The overall soft volume environment has acted as a dampener for the company.



from Biotech News